News

Pharmaceutical Technology on MSN12d
China’s CDE grants breakthrough status approval to Abbisko’s HCC therapy
The China NMPA's CDE has granted breakthrough therapy designation approval to Abbisko Therapeutics’ irpagratinib for HCC.
Morningstar12d
Abbisko Therapeutics Receives CDE Approval of Breakthrough Therapy Designation for Irpagratinib (ABSK011) in the Treatment of HCC
About Irpagratinib (ABSK-011) Irpagratinib is a highly-selective FGFR4 small molecule inhibitor designed to target overexpression of the FGF19 signaling pathway. Several epidemiological studies ...
Pharmabiz11d
China NMPA grants breakthrough therapy designation to Abbisko Therapeutics’ irpagratinib to treat hepatocellular carcinoma
China NMPA grants breakthrough therapy designation to Abbisko Therapeutics’ irpagratinib to treat hepatocellular carcinoma: Shanghai Tuesday, May 27, 2025, 10:00 Hrs [IST] Abbis ...
WGN Radio25d
Abbisko Therapeutics to Present Updated Results from the Phase 2 Study of Irpagratinib in Combination with Atezolizumab for the Treatment of Advanced Hepatocellular Carcinoma ...
Irpagratinib is a highly-selective FGFR4 small molecule inhibitor designed to target overexpression of the FGF19 signaling pathway. Several epidemiological studies indicate that approximately 30% of ...
KELOLAND News25d
Abbisko Therapeutics to Present Updated Results from the Phase 2 Study of Irpagratinib in Combination with Atezolizumab for the Treatment of Advanced Hepatocellular Carcinoma ...
Irpagratinib is a highly-selective FGFR4 small molecule inhibitor designed to target overexpression of the FGF19 signaling pathway. Several epidemiological studies indicate that approximately 30% ...
Taiwan News12d
Abbisko Therapeutics Receives CDE Approval of Breakthrough Therapy Designation for Irpagratinib (ABSK011) in the Treatment of HCC
To date, no FGFR4 inhibitor has been granted regulatory approval globally. According to Frost & Sullivan, irpagratinib is expected to become the first breakthrough treatment for the treatment of HCC ...